Switch theme
Sign up to access all valuation multiples
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
1972
12.3K+
Last FY Revenue $313M
Last FY EBITDA $56.0M
$582M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Renata achieved revenue of $313M and an EBITDA of $56.0M.
Renata expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Renata valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $313M | XXX | XXX | XXX |
| Gross Profit | XXX | $138M | XXX | XXX | XXX |
| Gross Margin | XXX | 44% | XXX | XXX | XXX |
| EBITDA | XXX | $56.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 18% | XXX | XXX | XXX |
| EBIT | XXX | $42.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 14% | XXX | XXX | XXX |
| Net Profit | XXX | $30.0M | XXX | XXX | XXX |
| Net Margin | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | $121M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Renata's stock price is BDT 471 (or $4).
Renata has current market cap of BDT 54.0B (or $448M), and EV of BDT 70.2B (or $582M).
See Renata trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $582M | $448M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Renata has market cap of $448M and EV of $582M.
Renata's trades at 1.8x EV/Revenue multiple, and 10.3x EV/EBITDA.
Equity research analysts estimate Renata's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Renata's P/E ratio is not available.
See valuation multiples for Renata and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $448M | XXX | $448M | XXX | XXX | XXX |
| EV (current) | $582M | XXX | $582M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 16.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -99.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRenata's revenue per employee in the last FY averaged $25K, while opex per employee averaged $8K for the same period.
Renata's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Renata's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Renata and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $25K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $8K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Renata acquired XXX companies to date.
Last acquisition by Renata was XXXXXXXX, XXXXX XXXXX XXXXXX . Renata acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Renata founded? | Renata was founded in 1972. |
| Where is Renata headquartered? | Renata is headquartered in Bangladesh. |
| How many employees does Renata have? | As of today, Renata has 12.3K+ employees. |
| Who is the CEO of Renata? | Renata's CEO is Mr. Kaiser Kabir. |
| Is Renata publicy listed? | Yes, Renata is a public company listed on DHA. |
| What is the stock symbol of Renata? | Renata trades under RENATA ticker. |
| Who are competitors of Renata? | Similar companies to Renata include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Renata? | Renata's current market cap is $448M |
| Is Renata profitable? | Yes, Renata is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
